The PK characteristics of pola in patients with DLBCL in the phase II expansion arms receiving pola 1.8 mg/kg + R/G-CHP were generally similar to those in patients with mixed subtype B-NHL in the phase Ib dose-escalation study at the same dose level. The gene discussed is POLA1; the disease is diffuse large B-cell lymphoma.